Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management
Ainos announced the global launch of Atmosphere Engine, a platform designed to generate high-purity nitrogen and oxygen on-site, extending its capabilities from environmental sensing to active environmental management.
The system targets AI infrastructure and semiconductor manufacturing, and is designed to require approximately one-third of the electricity used by conventional molecular sieve-based systems to reduce oxidation and improve asset reliability.
CEO Eddy Tsai emphasized the goal of simplifying infrastructure economics and creating measurable value by solving real customer problems through localized gas generation.